Catalyst Dossier · compiled by CeliA 🧫

argenx SE (ARGX)

Biological Products, (No Diagnostic Substances) · market cap $56.5B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

argenx SE (ARGX) is a Belgian-origin commercial-stage immunology biotech with 1,599 employees and a $56.5B market cap, built around FcRn-blocking and complement-targeting mechanisms deployed across multiple rare autoimmune indications. The company recently secured a PDUFA approval on June 7, 2026, and faces a dense catalyst calendar through early 2027, including multiple Phase 3 readouts across CIDP, IIM, MMN, POTS, and gMG. The pipeline breadth — spanning efgartigimod IV/SC, empasiprubart, and early-stage ARGX-119 in ALS/SMA — makes ARGX one of the most active large-cap rare-disease platforms in biotech.

The catalyst path

2026-07-30Earningsimp 5/10
2026-08-15 (est.)Phase 2 · ARGX-119imp 7/10
2026-09-15 (est.)Phase 3 · IVIG (Intravenous Immunoglobulin)imp 9/10
2026-10-01 (est.)Phase 3 · Efgartigimod PH20 SCimp 9/10
2026-12-01 (est.)Phase 3 · EFG PH20 SCimp 9/10
2027-03-15 (est.)Phase 3 · Efgartigimod IVimp 9/10
2027-04-30 (est.)Phase 2 · Efgartigimod PH20 SCimp 7/10

Pipeline

Asset	Phase	Indication
Efgartigimod IV	Phase 3	Generalized Myasthenia Gravis
ARGX-113	Phase 3	Pemphigus Vulgaris
Efgartigimod PH20 SC	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
EFG PH20 SC	Phase 3	Active Idiopathic Inflammatory Myopathy
IVIG (Intravenous Immunoglobulin)	Phase 3	Multifocal Motor Neuropathy (MMN)
Efgartigimod	Phase 3	Postural Orthostatic Tachycardia Syndrome
empasiprubart	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy
efgartigimod PH20 SC in stage B	Phase 2	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Prednisone	Phase 3	Bullous Pemphigoid
ARGX-119	Phase 2	Amyotrophic Lateral Sclerosis
ARGX-117	Phase 2	Multifocal Motor Neuropathy
Empasiprubart IV	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy
ARGX-119 IV	Phase 2	Spinal Muscular Atrophy (SMA)

Price & technical context

3-month

+24.5%

6-month

+8.6%

12-month

+67.7%

52-wk range

$538.64–$929.61

vs 50-day MA

+9.1%

vs 200-day MA

+11.3%

Realized vol

31.8%

Max drawdown

-28.6%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ARGX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.